August 20, 2025 - 00:18

Greenhaven Road Capital, an investment management firm, recently shared insights from its second-quarter 2025 investor letter. The letter highlights a notable performance for the fund, which achieved a return of approximately +14% net of fees and expenses during the quarter. This positive outcome, however, contrasts with year-to-date (YTD) returns that currently sit at just under +1%.
The letter discusses the broader market context, referencing the Russell 2000 index, which serves as a benchmark for small-cap stocks. Despite the challenges faced in the market, the fund's performance in the second quarter indicates a potential rebound and reflects the investment team's strategic decisions.
Investors are keenly observing PAR Technology, as it presents high expected value, albeit with uncertain timing for significant returns. The investment landscape remains dynamic, and stakeholders are encouraged to remain vigilant as market conditions evolve. The insights shared in the letter provide a glimpse into the fund's outlook and its approach to navigating these complexities.
September 30, 2026 - 21:59
Micron Technology Tops Lofty Fiscal Q4 Goals, Guides Above ViewsMicron Technology exceeded analyst expectations for its fiscal fourth quarter, delivering results that outperformed even the most optimistic projections on Wall Street. The memory chip maker...
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...